www.celexoncology.com
Open in
urlscan Pro
198.49.23.145
Public Scan
Submitted URL: http://celexoncology.com/
Effective URL: https://www.celexoncology.com/
Submission: On February 09 via manual from PH — Scanned from DE
Effective URL: https://www.celexoncology.com/
Submission: On February 09 via manual from PH — Scanned from DE
Form analysis 0 forms found in the DOM
Text Content
0 Skip to Content Current Page: Home Research Mechanism Publications Patents Media News Team Contact Open Menu Close Menu Open Menu Close Menu Current Page: Home Research Mechanism Publications Patents Media News Team Contact Current Page: Home Research Mechanism Publications Patents Media News Team Contact MAKING INVASIVE TUMOURS BENIGN CELEX ONCOLOGY FOCUSES ON TREATING AGGRESSIVE, INVASIVE AND METASTATIC CANCER FORMS. Celex is a spin-off from Imperial College, that captures the ground breaking work of Professor Mustafa Djamgoz that has the potential to turn cancer from a life-threatening disease to a chronic illness like high blood pressure. Professor Djamgoz, pioneered the research that electrical changes in cancer cells turns them from being benign to metastatic cells. The key breakthrough is that cancer cells develop a unique electrical channel (neonatal voltage-gated sodium channel) that allows sodium ions to continuously flow into the cells. Through a series of events this, leads to the cancer cells become metastatic and pass into the blood stream to land on secondary organs. This is a mechanism of action discovery, and it has the potential to be pan-carcinoma. For all metastatic cancer forms that have investigated, this have been found this to be the case Celex has two clear strategies to revolutionise the way cancer is treated: o Daily tablets made from a patented combination of drugs to stop the persistent current of the voltage-gated sodium channel. This solution has the potential to completely alter the system-wide economics of managing cancer o Develop a highly selective mAb to directly attack the neonatal channels which can be used in therapies such as immunotherapy INDICATIONS. We are targeting breast and colon cancer. Approximately 12 % of all women and 2,2% of all men are diagnosed with one of the diseases before the age of 75 TECHNOLOGY. The CELEX mechanism describes how a tumour transforms from being a benign tumour into an aggressive and invasive tumour. NEXT TREATMENT. Immunotherapy based on our propriatary mAb Vaccine focusing on our target Traditional oral medication through our proprietairy drug CONTACT US. info@celex-oncology.com Tel: +44 7961 816959 CELEX ONCOLOGY. Registered Office 64 New Cavendish Street London W1G 8TB United Kingdom By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.